Role of nacetyl cysteine in viral hepatitis

Reading File

Finding Sources

Searching PubMed

"N-acetylcysteine" AND "viral hepatitis"

Reading File

Searching PubMed

"N-acetylcysteine" AND "acute liver failure" AND hepatitis

Reading File

Reading Article

PMID: 35371352

Loading Image

I now have all the information needed for a thorough, well-illustrated answer.

N-Acetylcysteine (NAC) in Viral Hepatitis

Mechanism of Action

NAC works through several complementary pathways relevant to hepatic injury:

Glutathione replenishment - NAC is a precursor of L-cysteine, which is the rate-limiting substrate for intracellular glutathione (GSH) synthesis. It replenishes both mitochondrial and cytosolic GSH stores depleted during hepatic oxidative stress.
Direct antioxidant - Acts as a free radical scavenger (particularly against hydroxyl and superoxide radicals).
Improved hepatic microcirculation - Increases nitric oxide bioavailability, improving sinusoidal blood flow and oxygen delivery to hepatocytes.
Anti-inflammatory effects - Reduces NF-κB activation and pro-inflammatory cytokine production (TNF-α, IL-1β).
Mitochondrial protection - Prevents mitochondrial permeability transition pore opening, a key step in hepatocyte apoptosis/necrosis.

Lippincott Illustrated Reviews: Pharmacology, NAC works as a "glutathione precursor and glutathione substitute and assists with sulfation... [and] may also function as an antioxidant to aid in recovery"

1. Acute Viral Hepatitis Causing Acute Liver Failure (ALF)

This is the most clinically important context. Viral hepatitis - particularly hepatitis B (acute or reactivation) - is a leading cause of non-acetaminophen ALF worldwide.

The Landmark RCT (Lee et al., 2009 - Acute Liver Failure Study Group)

A randomized, placebo-controlled, double-blind trial of IV NAC in non-acetaminophen ALF found:

Overall survival: 70% (NAC) vs. 66% (placebo) - not statistically significant (p < 0.28)
Transplant-free survival (overall): 40% (NAC) vs. 27% (placebo) - p < 0.04 (significant)
Early encephalopathy (grades I-II): Transplant-free survival 52% (NAC) vs. 30% (placebo) - p < 0.01
Advanced encephalopathy (grades III-IV): No benefit; transplant-free survival actually lower with NAC (8% vs. 22%, p < 0.09 - not significant but trend against NAC)

Kaplan-Meier survival curves from the NAC trial in non-acetaminophen acute liver failure, showing transplant-free survival by coma grade. NAC grades I-II (blue) dramatically outperforms all other groups over 365 days.

Bar graph of NAC trial outcomes showing statistically significant improvements in transplant-free survival (especially coma grades I-II) with NAC vs. placebo in non-acetaminophen ALF.

Hepatitis B Subgroup (Key Data)

The HBV subgroup showed the greatest benefit from NAC:

Outcome	Placebo (n=12)	NAC (n=25)
Overall survival	50% (6/12)	76% (19/25)
Transplant-free survival	17% (2/12)	40% (10/25)

"Drug-induced liver injury and hepatitis B (in bold) demonstrated the greatest differences in rates of spontaneous survival in these small patient subsets." - Yamada's Textbook of Gastroenterology, 7th ed.

Clinical Implication

Based on this, Goldman-Cecil Medicine recommends:

"N-acetylcysteine is also commonly recommended in acute liver failure caused by idiosyncratic drug-induced liver injury, hepatitis B, and autoimmune hepatitis, as well as acute liver failure of indeterminate cause, especially in patients who have grade 1 or 2 encephalopathy."

2. Alcoholic Hepatitis

NAC has been studied as an adjunct to corticosteroids in severe alcoholic hepatitis (discriminant function > 32):

Harrison's Principles of Internal Medicine (2025) states: "There is modest evidence that intravenous N-acetylcysteine plus glucocorticoids may have a short-term survival benefit in alcoholic hepatitis if the DF is >32."
It is not recommended as monotherapy, and is considered adjunctive with uncertain long-term benefit.

3. Meta-Analysis Evidence (2022)

A systematic review and meta-analysis by Amjad et al. (2022) pooling 672 patients from 5 prospective studies (viral hepatitis was the most common etiology at ~46% of NAC-treated patients) found:

Transplant-free survival: 55.1% (NAC) vs. 28.1% (control) - RR = 0.56, 95% CI: 0.33-0.94 (significant)
Overall survival: 71% vs. 59.8% - RR = 0.73, 95% CI: 0.48-1.09 (not significant)
Hospital stay: Significantly shorter with NAC (SMD = -1.62, p < 0.001)

Conclusion from meta-analysis: NAC significantly improves transplant-free survival and shortens hospital stay, though it does not significantly reduce overall mortality when transplantation is available.

4. Other Viral Etiologies

Hepatitis A/E causing ALF: No specific RCT data, but NAC is used empirically given its safety profile and the plausible mechanism.
Herpes simplex hepatitis: Acyclovir is the specific treatment, but NAC may be co-administered for ALF support.
Viral hepatitis in at-risk patients: Patients with pre-existing viral hepatitis (chronic HBV/HCV) are at heightened risk of acetaminophen hepatotoxicity due to depleted GSH reserves. NAC is first-line in any suspected acetaminophen overdose in this population. - Lippincott Illustrated Reviews: Pharmacology

Dosing

Route	Protocol
IV (preferred in ALF)	150 mg/kg over 60 min (loading), then 12.5 mg/kg/hr x 4 hr, then 6.25 mg/kg/hr x 16 hr (standard 21-hr protocol)
Oral	140 mg/kg loading dose, then 70 mg/kg every 4 hours x 17 doses

IV is preferred in ALF because oral absorption may be impaired in critically ill patients, and IV NAC also directly reduces risk of hypotension, cerebral edema, and death.

Key Takeaways

Clinical Context	Evidence	Recommendation
HBV-related ALF (early encephalopathy)	RCT + meta-analysis	Use IV NAC (strongest evidence)
Non-acetaminophen ALF (grades I-II)	RCT (Lee 2009)	Use IV NAC
Non-acetaminophen ALF (grades III-IV)	No benefit in RCT	Use with caution / bridge to transplant
Alcoholic hepatitis (severe, DF >32)	Limited RCT data	NAC + corticosteroids (adjunct)
Viral hepatitis + APAP overdose	Strong evidence	NAC is standard of care
Chronic viral hepatitis	No direct evidence	Not routinely recommended

The therapeutic window is narrow - NAC benefits are most pronounced when started early, in patients with mild-to-moderate encephalopathy (grades I-II). Once advanced encephalopathy develops, liver transplantation evaluation takes priority.

This is a shared conversation. Sign in to Orris to start your own chat.